Triple-Negative Breast Cancer (TNBC) is a subtype of breast cancer that tests negative for estrogen receptor, progesterone receptor, and human epidermal growth factor-2 receptor (HER2), according to the American Cancer Society. It remains one of the most aggressive subtypes of breast cancer. The main risk factor of this disease is the use of oral contraceptives in younger women (less than 50 years old) for longer than one year. The standard of care for TNBC remains chemotherapy. Other treatment options that have proven to improve overall survival include Surgery, radiotherapy, immunotherapy, targeted therapy, and antibody-drug conjugates. Several clinical trials are still ongoing to develop more effective and targeted treatments that improve survival and reduce the toxicity profile.